Research Topics
Species | Daniel VittecoqSummaryCountry: France Publications
| Collaborators
|
Detail Information
Publications
Coronary heart disease in HIV-infected patients in the highly active antiretroviral treatment eraDaniel Vittecoq
Service des Maladies Infectieuses et de Médecine Interne, Hopital Paul Brousse, Villejuif, France
AIDS 17:S70-6. 2003..To assess the incidence and the clinical features of coronary heart disease in HIV-infected patients. To assess atherosclerosis risk factors in this population...- [Liver transplantation: is it possible in HIV/HCV co-infected patients?]D Vittecoq
Service des Maladies Infectieuses, Hopital Paul Brousse, 12 14, avenue Paul Vaillant Couturier, 94800 Villejuif, France
Pathol Biol (Paris) 51:525-7. 2003..Finally, liver transplantation in HIV-HCV co-infected patients seems to be feasible when strict criteria of selection are taken into account. This still experimental strategy requires a multidisciplinary partnership... - Coronary heart disease in HIV-infected individualsDaniel Vittecoq
Service des Maladies Infectieuses, , Villejuif, France
Adv Cardiol 40:151-62. 2003 
Enfuvirtide: a safe and effective antiretroviral agent for human immunodeficiency virus-infected patients shortly after liver transplantationElina Teicher
Département Médecine Interne et Infectiologie, AP HP Hopital Paul Brousse, Villejuif, France
Liver Transpl 15:1336-42. 2009..Moreover, the lack of liver toxicity renders this drug valuable in the event of a severe HCV recurrence...- Coronary artery disease in HIV infected patientsLelia Escaut
Service des Maladies Infectieuses, , 12-14 avenue Paul Vaillant Couturier, 94804, Villejuif, France
Intensive Care Med 29:969-73. 2003..However, treatment and prognosis of acute myocardial infarction has no specificity... - Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virusJean Charles Duclos-Vallée
Centre Hepato Biliaire, AP HP Hopital Paul Brousse, Villejuif, France
Hepatology 47:407-17. 2008.... - Efficacy of etravirine for treatment of acute HIV meningoencephalitisCarine Couzigou
Services des Maladies Infectieuses et Tropicales and Virologie, Assistance Publique Hôpital de Paris, Hopital Paul Brousse, Villejuif, France
Clin Infect Dis 48:e62-5. 2009..Etravirine has a satisfactory safety profile and, in this case, was a durable alternative therapy for HIV meningoencephalitis... - Relationship between polymerase gamma (POLG) polymorphisms and antiretroviral therapy-induced lipodystrophy in HIV-1 infected patients: a case-control studyFranck Chiappini
AP HP, Hopital Paul Brousse, Service de Biochimie et de Biologie Moléculaire, Université Paris 11, 12, avenue Paul Vaillant Couturier, Villejuif Cedex, France
Curr HIV Res 7:244-53. 2009..These could be due to decreased content of mtDNA in PBMC in these patients. Therefore, the toxicity of NRTIs leading to lipodystrophy in some HIV-1 infected patients could be explained in part by the occurrence of POLG polymorphisms... - Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 studyElina Teicher
Internal Medicine and Infectious Diseases Department, Hopital Paul Brousse, Assistance Publique Hopitaux de Paris AP HP, Paris, France
Clin Pharmacokinet 46:941-52. 2007..To characterise the interactions between tacrolimus and antiretroviral drug combinations in hepatitis C virus-HIV co-infected patients who had received a liver transplant... - [Liver transplantation for patients infected with both HIV and HCV or HIV and HBV]Jean Charles Duclos-Vallée
Département des Maladies du Foie et INSERM U785, Unité de maladies infectieuses, Universite Paris XI, Centre Hepato Biliaire, Hopital Paul Brousse, 12 14, avenue Paul Vaillant Couturier, 94804, Villejuif, France
Med Sci (Paris) 23:723-8. 2007..Understanding HCV recurrence mechanisms, and preventing and treating of HCV recurrence are major future challenges... - Cytokines in HIV-associated cardiomyopathyJean Jacques Monsuez
AP HP, Hopital Paul Brousse, Department of Internal Medicine and Infectious Diseases, Universite Paris Sud 11, Faculte de Medecine, de Bicêtre, France 94804 Villejuif, France
Int J Cardiol 120:150-7. 2007..Whether modulation of TNF production or selective inhibition of p38 MAPK pathway could be useful approaches remains uncertain... - Non-O:1 and non-O:139 Vibrio cholerae septicemia and pyomyositis in an immunodeficient traveler returning from TunisiaCarine Couzigou
Unit of Infectious Diseases and Tropical Medicine, , , , 12 avenue PV Couturier, 94804 Villejuif, France
Travel Med Infect Dis 5:44-6. 2007 - Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre studyHassane Izzedine
Department of Nephrology, Pitie Salpetriere Hospital, 47 83 boulevard de l Hopital, 75013 Paris, France
Nephrol Dial Transplant 20:743-6. 2005..However, controlled data are sparse on the long-term renal tolerability of TDF at the currently approved daily dose of 300 mg in treatment-naive HIV-infected patients... - Hepatitis C virus viral recurrence and liver mitochondrial damage after liver transplantation in HIV-HCV co-infected patientsJean Charles Duclos-Vallée
Centre Hépato Biliaire Hôpital Paul Brousse, Assistance Publique Hopitaux de Paris, 94804 Villejuif, France
J Hepatol 42:341-9. 2005..We report the Paul Brousse Hospital experience of transplantation for end stage cirrhosis in HIV-HCV co-infected patients... - [Liver transplantation in patients with HIV: indications, limits, perspectives]Didier Samuel
, UPRES 3541, ,
Gastroenterol Clin Biol 27:372-4. 2003 
Enhanced saquinavir exposure in human immunodeficiency virus type 1-infected patients with diarrhea and/or wasting syndromeHervé Trout
Laboratoire de Toxicologie et Pharmacologie Clinique, Service de Pharmacie, Hopital Lariboisiere, Paris, France
Antimicrob Agents Chemother 48:538-45. 2004..This must be evaluated in a long-term period...- Prospective evaluation of blood concentration of mitochondrial DNA as a marker of toxicity in 157 consecutively recruited untreated or HAART-treated HIV-positive patientsFranck Chiappini
, , 12 avenue Paul Vaillant-Couturier, 94800 Villejuif, France
Lab Invest 84:908-14. 2004..Thus, the mtDNA to nDNA ratio in leukocytes does not seem to be an accurate marker of mild and/or long-term mitochondrial toxicity... - Liver transplantation in patients with HIV infectionDidier Samuel
, UPRES 3541, Recherche Association Claude Bernard Virus et Transplantation, , , AP-HOP Paris, 14 avenue Paul Vaillant Couturier, 94800 Villejuif, France
J Hepatol 39:3-6. 2003 - Mitochondrial damage associated with long-term antiretroviral treatment: associated alteration or causal disorder?Daniel Vittecoq
Unité des maladies infectieuses, Hopital Paul Brousse, Villejuif, France
J Acquir Immune Defic Syndr 31:299-308. 2002..Its severity argues for its clinical relevance, however. The skewed tissue distribution of mitochondrial alterations indicates potential pitfalls in the needed future prospective studies... - Initial human herpesvirus-8 rash and multicentric Castleman diseaseBenjamin Wyplosz
Unité des Maladies Infectieuses et Tropicales, Hopital Paul Brousse, Villejuif, Paris, France
Clin Infect Dis 47:684-8. 2008..We document the first case, to our knowledge, of HHV-8-induced rash and suggest that circulating plasmablasts drive HHV-8 to target tissues... - Urolithiasis in HIV-positive patients treated with atazanavirCarine Couzigou
Service des Maladies Infectieuses et Tropicales, AP HP, Hopital Paul Brousse, Villejuif, France
Clin Infect Dis 45:e105-8. 2007..Patients with low water intake, high urinary pH, and a prior history of urinary stones may have a higher risk of atazanavir-associated urine crystallization... - [Anti-Jo1 antibodies syndrome in an HIV-infected patient]Carine Salliot
Unité de maladies infectieuses et tropicales, Centre Hospitalier Universitaire Paul Brousse, 14, avenue Paul Vaillant Couturier, BP 200, 94804 Villejuif Cedex, France
Ann Med Interne (Paris) 153:209-10. 2002..Anti-Jo1 antibodies are exceptional in HIV-infected patients. We discuss the role of infection in polymyositis. HAART and corticosteroids led to rapid clinical and radiological improvement... - Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trialBeatriz Grinsztejn
Evandro Chagas Clinical Research Institute Oswaldo Cruz Foundation, Rio de Janeiro, Brazil
Lancet 369:1261-9. 2007..The aim of this study was to assess the safety and efficacy of raltegravir when added to optimised background regimens in HIV-infected patients... - Renal safety of tenofovir in HIV treatment-experienced patientsHassane Izzedine
Department of Nephrology, , Paris, France
AIDS 18:1074-6. 2004..Proximal tubulopathy was diagnosed 6.89 +/- 5.51 months after TDF therapy started. All abnormalities normalized within 4.7 +/- 2.94 weeks after drug discontinuation... - The pavia consensus statementPaul A Volberding
University of California, San Francisco, USA
AIDS 17:S170-9. 2003 - [The HIV-infected traveler: infectious risks and prevention]Carine Couzigou
Service des Maladies Infectieuses et Tropicales, AP HP Hopital Paul Brousse, F 94800 Villejuif, France
Presse Med 37:490-9. 2008..Some countries have entry restriction for travelers with HIV. Special precautions may be necessary for transporting and storing antiretroviral medications... - Repertoire, diversity, and differentiation of specific CD8 T cells are associated with immune protection against human cytomegalovirus diseaseKarim Sacre
Laboratoire d'Immunologie Cellulaire et Tissulaire, INSERM U543, , , 75013 Paris, France
J Exp Med 201:1999-2010. 2005.... - Brief report: carotid intima-media thickness in heavily pretreated HIV-infected patientsGilles Chironi
, , 96 rue Didot, 75674 Paris Cedex 14, France
J Acquir Immune Defic Syndr 32:490-3. 2003..This case-control study suggests that lipid disturbances, mainly hypoHDLemia, may be involved in the early atherosclerotic process in HIV-infected patients... - Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094)Roland Tubiana
, INSERM E0214, , Paris, France
Vaccine 23:4292-301. 2005..Detection of such LPR response at the time of treatment interruption was significantly associated with the probability of remaining off therapy. These results provide rationale for future randomized trials exploring this strategy...